These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 35247806)

  • 21. Simplifying cancer: binary pan-cancer superclasses stratified by opposite YAP/TEAD effects.
    Pearson JD; Bremner R
    Mol Cell Oncol; 2021; 8(5):1981111. PubMed ID: 34859143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Author Correction: Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.
    Chapeau EA; Sansregret L; Galli GG; Chène P; Wartmann M; Mourikis TP; Jaaks P; Baltschukat S; Barbosa IAM; Bauer D; Brachmann SM; Delaunay C; Estadieu C; Faris JE; Furet P; Harlfinger S; Hueber A; Jiménez Núñez E; Kodack DP; Mandon E; Martin T; Mesrouze Y; Romanet V; Scheufler C; Sellner H; Stamm C; Sterker D; Tordella L; Hofmann F; Soldermann N; Schmelzle T
    Nat Cancer; 2024 Jul; 5(7):1130. PubMed ID: 38886525
    [No Abstract]   [Full Text] [Related]  

  • 23. CK2-induced cooperation of HHEX with the YAP-TEAD4 complex promotes colorectal tumorigenesis.
    Guo Y; Zhu Z; Huang Z; Cui L; Yu W; Hong W; Zhou Z; Du P; Liu CY
    Nat Commun; 2022 Aug; 13(1):4995. PubMed ID: 36008411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiproliferative and Antimigratory Effects of a Novel YAP-TEAD Interaction Inhibitor Identified Using in Silico Molecular Docking.
    Smith SA; Sessions RB; Shoemark DK; Williams C; Ebrahimighaei R; McNeill MC; Crump MP; McKay TR; Harris G; Newby AC; Bond M
    J Med Chem; 2019 Feb; 62(3):1291-1305. PubMed ID: 30640473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of LM98, a Small-Molecule TEAD Inhibitor Derived from Flufenamic Acid.
    Mélin L; Abdullayev S; Fnaiche A; Vu V; González Suárez N; Zeng H; Szewczyk MM; Li F; Senisterra G; Allali-Hassani A; Chau I; Dong A; Woo S; Annabi B; Halabelian L; LaPlante SR; Vedadi M; Barsyte-Lovejoy D; Santhakumar V; Gagnon A
    ChemMedChem; 2021 Oct; 16(19):2982-3002. PubMed ID: 34164919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting the YAP-TEAD interaction interface for therapeutic intervention in glioblastoma.
    Saunders JT; Holmes B; Benavides-Serrato A; Kumar S; Nishimura RN; Gera J
    J Neurooncol; 2021 Apr; 152(2):217-231. PubMed ID: 33511508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of the acylation of TEAD4 on its interaction with co-activators YAP and TAZ.
    Mesrouze Y; Meyerhofer M; Bokhovchuk F; Fontana P; Zimmermann C; Martin T; Delaunay C; Izaac A; Kallen J; Schmelzle T; Erdmann D; Chène P
    Protein Sci; 2017 Dec; 26(12):2399-2409. PubMed ID: 28960584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of Small-molecule YAP-TEAD inhibitors by High-throughput docking for the Treatment of colorectal cancer.
    Li L; Li R; Wang Y
    Bioorg Chem; 2022 May; 122():105707. PubMed ID: 35247806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic targeting of TEAD transcription factors in cancer.
    Pobbati AV; Kumar R; Rubin BP; Hong W
    Trends Biochem Sci; 2023 May; 48(5):450-462. PubMed ID: 36709077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
    Crawford JJ; Bronner SM; Zbieg JR
    Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
    [No Abstract]   [Full Text] [Related]  

  • 31. Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present).
    Zagiel B; Melnyk P; Cotelle P
    Expert Opin Ther Pat; 2022 Aug; 32(8):899-912. PubMed ID: 35768160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances of targeting the YAP/TAZ-TEAD complex in the hippo pathway for the treatment of cancers.
    Luo M; Xu Y; Chen H; Wu Y; Pang A; Hu J; Dong X; Che J; Yang H
    Eur J Med Chem; 2022 Dec; 244():114847. PubMed ID: 36265280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthetic molecules targeting yes associated protein activity as chemotherapeutics against cancer.
    Iftikhar R; Zahoor AF; Irfan M; Rasul A; Rao F
    Chem Biol Drug Des; 2021 Dec; 98(6):1025-1037. PubMed ID: 34587361
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.